Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental | AS1411 treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AS1411 | Drug | AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles |
|
| Measure | Description | Time Frame |
|---|---|---|
| To determine the Overall Response Rate to AS1411 |
| Measure | Description | Time Frame |
|---|---|---|
| To measure progression free survival with AS1411 | ||
| To measure time to disease progression with AS1411 | ||
| To measure the duration of overall response and stable disease with AS1411 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Greg Smith, MD | Saint Francis Hospital | Principal Investigator |
| Harry Drabkin, MD | Medical University of South Carolina | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | United States | ||
| University of California, Davis Cancer Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24242861 | Derived | Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2014 Feb;32(1):178-87. doi: 10.1007/s10637-013-0045-6. Epub 2013 Nov 16. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002292 | Carcinoma, Renal Cell |
| D007680 | Kidney Neoplasms |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| C513936 | AGRO 100 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| To determine the safety and tolerability of two cycles of AS1411 |
| To assess the pharmacokinetic profile of AS1411 |
| To assess pharmacodynamic markers of AS1411 |
| Sacramento |
| California |
| 95817 |
| United States |
| University of California San Francisco | San Francisco | California | 94143 | United States |
| St Francis Hospital | Beech Grove | Indiana | 46107 | United States |
| James Graham Brown Cancer Center, University of Louisville | Louisville | Kentucky | 40202 | United States |
| Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | United States |
| Medical University of South Carolina | Charleston | South Carolina | 29403 | United States |
| D009369 | Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |